Oral citrulline supplementation protects female mice from the development of non-alcoholic fatty liver disease (NAFLD)

被引:30
|
作者
Sellmann, Cathrin [1 ]
Jin, Cheng Jun [1 ]
Engstler, Anna Janina [1 ]
De Bandt, Jean-Pascal [2 ,3 ]
Bergheim, Ina [1 ]
机构
[1] Friedrich Schiller Univ Jena, Inst Nutr Sci, SD Model Syst Mol Nutr, Dornburger Str 29, D-07743 Jena, Germany
[2] Paris Descartes Univ, Sorbonne Paris Cite, Nutr Biol Lab EA4466, Fac Pharm, Paris, France
[3] Paris Ctr Univ Hosp, APHP, Clin Chem Dept, Paris, France
关键词
Citrulline; Intestinal barrier function; Endotoxin; Occludin; Non-alcoholic fatty liver disease; TOLL-LIKE RECEPTORS; INSULIN-RESISTANCE; NITRIC-OXIDE; STEATOHEPATITIS; ARGININE; REPERFUSION; PROGRESSION; PREVALENCE; WATERMELON; NUTRITION;
D O I
10.1007/s00394-016-1287-9
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Purpose Impairments of intestinal barrier function are discussed as risk factors for the development and progression of non-alcoholic fatty liver disease (NAFLD). Studies suggest an association between arginine/citrulline homeostasis and the development of liver damages. Here, the effect of an oral l-citrulline (Cit) supplement on the development of a Western-style diet (WSD)-induced NAFLD was determined in mice. Methods Female 6- to 8-week-old C57BL/6J mice were either pair-fed a liquid Western-style or control diet (C) +/- 2.5 g/kg bodyweight Cit for 6 weeks (C + Cit or WSD + Cit). Indices of liver damage, glucose metabolism, intestinal barrier function and NO synthesis were measured. Results While bodyweight gain was similar between groups, markers of glucose metabolism like fasting blood glucose and HOMA index and markers of liver damage like hepatic triglyceride levels, number of neutrophils and plasminogen activator inhibitor-1 protein levels were significantly lower in WSD + Cit-fed mice when compared to WSD-fed mice only. Protein levels of the tight junction proteins occludin and zonula occludens-1 in duodenum were significantly lower in mice fed a WSD when compared to those fed a WSD + Cit (-similar to 70 and -similar to 60 %, respectively, P < 0.05), whereas portal endotoxin levels, concentration of 3-nitrotyrosine protein adducts in duodenum and toll-like receptor-4 mRNA expression in livers of WSD + Cit-fed mice were markedly lower than in WSD-fed mice (-similar to 43 %, P = 0.056; -similar to 80 and -similar to 48 %, respectively, P < 0.05). Conclusion Our data suggest that the protective effects of supplementing Cit on the development of NAFLD in mice are associated with a decreased translocation of endotoxin into the portal vein.
引用
收藏
页码:2519 / 2527
页数:9
相关论文
共 50 条
  • [21] Non-alcoholic Fatty Liver Disease Diagnosis and Therapy of NAFLD
    不详
    GASTROENTEROLOGE, 2021, 16 (05): : 386 - 386
  • [22] A lipidomic analysis of non-alcoholic fatty liver disease (NAFLD)
    Puri, P.
    Baillie, R. A.
    Wiest, M.
    Mirshahi, F.
    Sanyal, A. J.
    JOURNAL OF HEPATOLOGY, 2006, 44 : S260 - S261
  • [23] Irisin Is Related to Non-Alcoholic Fatty Liver Disease (NAFLD)
    Kosmalski, Marcin
    Drzewoski, Jozef
    Szymczak-Pajor, Izabela
    Zieleniak, Andrzej
    Mikolajczyk-Solinska, Melania
    Kasznicki, Jacek
    Sliwinska, Agnieszka
    BIOMEDICINES, 2022, 10 (09)
  • [24] Antiepileptic drugs and non-alcoholic fatty liver disease (NAFLD)
    Waldmann, M
    Sturm, W
    Naser, A
    Unterberger, I
    Trinka, E
    Bauer, G
    Lechleitner, M
    Luef, G
    EPILEPSIA, 2004, 45 : 161 - 162
  • [25] Diagnosis and management of non-alcoholic fatty liver disease (NAFLD)
    Byrne, C. D.
    POSTGRADUATE MEDICAL JOURNAL, 2018, 94 : A2 - A2
  • [26] Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)
    Rong, Li
    Zou, Junyan
    Ran, Wei
    Qi, Xiaohong
    Chen, Yaokai
    Cui, Hongjuan
    Guo, Jinjun
    FRONTIERS IN ENDOCRINOLOGY, 2023, 13
  • [27] Recommendations for the management of non-alcoholic fatty liver disease (NAFLD)
    Tomasiewicz, Krzysztof
    Flisiak, Robert
    Halota, Waldemar
    Jaroszewicz, Jerzy
    Lebensztejn, Dariusz
    Lisik, Wojciech
    Malkowski, Piotr
    Pawlowska, Malgorzata
    Piekarska, Anna
    Simon, Krzysztof
    Tronina, Olga
    CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2018, 4 (03) : 153 - 157
  • [28] Prevalence of non-alcoholic fatty liver disease (NAFLD) in Singapore
    Tan, H. H.
    Chang, J. P. E.
    Chin, C.
    Tan, C. K.
    Lui, H. F.
    Chow, W. C.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 : A444 - A445
  • [29] Non-Alcoholic Fatty Liver Disease (NAFLD) Management in the Community
    Park, Yongsoo
    Ko, Kyung Soo
    Rhee, Byoung Doo
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2025, 26 (06)
  • [30] NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND RESPIRATORY FUNCTIONS
    Ozkarafakili, Mufide Arzu
    Ga, Salih Bo
    Ozguven, M. Banu Yilmaz
    RESPIROLOGY, 2018, 23 : 198 - 198